Seoul National University Bundang Hospital ('SNUBH'), CurePSP, Inc. ('CurePSP') and GemVax & KAEL Co., Ltd. ('GemVax'; KOSDAQ: 082270) have announced the establishment of Korea's first International P ...
Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...
AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease.
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.